[Treatment of secondary hyperparathyroidism in hemodialysed patients--paricalcitol with or without cinacalcet].

Author: Dryl-RydzyńskaTeresa, MarcinkowskiWojciech, MałyszkoJacek, MałyszkoJolanta, PrystackiTomasz, ZawieruchaJacek

Paper Details 
Original Abstract of the Article :
Secondary hyperparathyroidism (sHPT) is a common complication being a consequence of metabolic disorders associated with chronic kidney disease (CKD). Treatment of the sHPT should lead to calcium-phosphate management stabilization and parathyroid hormone levels reduction. The phosphate binders, synt...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://pubmed.ncbi.nlm.nih.gov/27526425

データ提供:米国国立医学図書館(NLM)

Tackling Secondary Hyperparathyroidism in Hemodialysis Patients

This study examines the efficacy of paricalcitol, a synthetic vitamin D analog, in treating secondary hyperparathyroidism (sHPT) in hemodialysis patients. The researchers analyzed the effects of paricalcitol alone and in combination with cinacalcet, a calcimimetic drug, on patients with sHPT. The findings indicate that paricalcitol effectively reduced parathyroid hormone (PTH) levels and alkaline phosphatase levels, highlighting its potential as a treatment option for sHPT.

Paricalcitol: A Promising Treatment for Secondary Hyperparathyroidism

This research suggests that paricalcitol can play a significant role in managing sHPT in hemodialysis patients. The study's findings demonstrate the ability of paricalcitol to effectively reduce PTH levels, which is crucial for controlling calcium and phosphorus levels in the body. This drug could potentially improve the overall health and well-being of patients with sHPT.

Secondary Hyperparathyroidism: Living With Kidney Disease

Secondary hyperparathyroidism is a common complication of chronic kidney disease (CKD). It occurs when the kidneys are unable to properly regulate calcium and phosphorus levels in the blood, leading to an overproduction of PTH. This can result in bone disease, cardiovascular problems, and other health issues. While there is no cure for sHPT, proper management through medication and lifestyle modifications can significantly improve the quality of life for patients with CKD.

Dr.Camel's Conclusion

Secondary hyperparathyroidism is like a shifting sand dune, constantly changing and posing challenges for patients with CKD. This study shows that paricalcitol can help stabilize this dune, providing more predictable and manageable treatment options for those affected. While the journey with CKD can be long and demanding, research like this offers a glimmer of hope for patients seeking relief from the complications associated with this condition.

Date :
  1. Date Completed 2016-09-14
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

27526425

DOI: Digital Object Identifier

27526425

Related Literature

SNS
PICO Info
in preparation
Languages

Polish

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.